Kestra Medical intends to advance its mission of protecting at-risk patients with its WCD. Credit: Peakstock / Shutterstock.

Kestra Medical Technologies has secured $196m in an oversubscribed funding round to boost the commercialisation of the ASSURE wearable cardioverter defibrillator (WCD).

The investment will bolster the company’s commercial expansion and advance the WCD system.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The financing round was co-led by Ally Bridge Group, Andera Partners, Longitude Capital, and Omega Funds. It also saw participation from new investors such as T Rowe Price Investment Management, Eventide Asset Management, and Gilmartin Capital.

Existing investors Bain Capital and Endeavour Vision also made contributions in the round.

Kestra Medical Technologies president and CEO Brian Webster said: “This oversubscribed financing is a validation of the excitement and confidence that new and existing investors have for Kestra and our ASSURE cardiac recovery system which has been prescribed to well over 10,000 patients to date.

See Also:

“With this funding, our team is ready to aggressively compete and accelerate our commercialisation initiatives to transform the WCD market with our clinically proven system.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ASSURE is designed to offer autonomous detection and defibrillation for ventricular arrhythmias and records other significant arrhythmias that may require clinical intervention.

Equipped with four channels of ECG, an advanced algorithm, and adaptive patient intelligence, the ASSURE WCD can provide clear data and insights.

It is said to be the only WCD system that alerts an emergency medical services (EMS) operator via the ASSURE patient application after a defibrillation shock.

Kestra Medical’s comprehensive Cardiac Recovery System includes the ASSURE Wearable ECG, the ASSURE WCD, the patient-friendly ASSURE app, ASSURE Assist Services, and the Kestra CareStation for remote patient data management.